A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo

Triple-negative breast cancer (TNBC) remains the most lethal form of breast cancer, and effective targeted therapeutics are in urgent need to improve the poor prognosis of TNBC patients. Here, we report the development of a rationally designed antibody drug conjugate (ADC) for the treatment of late-...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Peng, Huang, Jing, Zhu, Bing, Huang, Andrew C., Jiang, Lingxiao, Fang, Jianmin, Moses, Marsha A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162665/
https://www.ncbi.nlm.nih.gov/pubmed/37146146
http://dx.doi.org/10.1126/sciadv.abq7866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162665/
https://www.ncbi.nlm.nih.gov/pubmed/37146146
http://dx.doi.org/10.1126/sciadv.abq7866

Ejemplares similares